Pixyl.Neuro reportedly leverages generative artificial intelligence (AI) technology to accelerate brain MRI assessment and improve early detection of abnormal atrophy.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Pixyl.Neuro™, an adjunctive artificial intelligence (AI)-powered software that may enhance magnetic resonance imaging (MRI) detection and follow-up of patients with neurological disorders including Alzheimer’s disease and multiple sclerosis (MS).
Reportedly providing automated brain MRI analysis in less than five minutes, Pixyl.Neuro may help quantify brain region volume to aid in the differential diagnosis and facilitate earlier identification of atrophy, according to Pixyl, the developer of the software.
Lotfi Hacein-Bey, M.D, said adjunctive AI support reinforces radiology workflows for the assessment of patients with neurological disorders.
“The recent FDA approval of Pixyl's software is a very positive step toward improved diagnosis, management and longitudinal follow up of neurodegenerative and neuroinflammatory disorders, especially with the advent of disease-modifying treatments for MS, NMO (neuromyelitis optica) and Alzheimer's disease,” noted Dr. Hacein-Bey, the director of the Division of Neuroradiology the the University of California, Davis (UC Davis) School of Medicine in Sacramento, Calif.
Pixyl added that the Pixyl.Neuro software, currently utilized in more than 12 countries, has seen a four-fold increase in use since December 2022.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.